The rational use of antibiotics in the treatment of community bronchopneumonia is a primary problem of medicine in terms of ensuring an effective and harmless pharmacotherapy and preventing the resistance development. cephalosporins have been and are one of the largest groups of antibiotics used for this purpose with an evolution over time of generations of drugs administered. A random retrospective analysis was performed for 242 indication sheets of patients with community bronchopneumonia hospitalized in the therapy departments no.1 and 2 of PMSI MCH no.1 during 2013-2019. The age of the patients ranged from 18 to 86 years. Among the hospitalized patients, 56 were only with community bronchopneumonia, and 186 with community bronchopneumonia associated with 1-3 comorbidities. In the treatment of community bronchopneumonia the monotherapy was used in 176 cases, and the combination therapy in 66. Among the cephalosporins as monotherapy for patients there were used cefazolin - 15, cefuroxime - 18, ceftazidime 10, ceftriaxone -129, and in combination with macrolides or fluoroquinolones - cefazolin at 3, cefuroxime at 4, ceftazidime at 11 and ceftriaxone at 40 patients. The cefazolin and cefuroxime were used as monotherapy, and only occasionally in combination with macrolides and fluoroquinolones, in the treatment of community bronchopneumonia mainly in 2013 and 2014. The relatively low use of ceftazidime can be argued by the specificity of the action spectrum, the influence on the pyocyanic bacillus, a microbe that may rarely be a pathogen of community bronchopneumonia. The broad and increased use of ceftriaxone is argued by the fact that the antibiotic mainly includes possible community bronchopneumonia agents and displays favorable pharmacokinetic properties. The restriction of the use of 1st and 2nd generation cephalosporins can be explained by the decrease in sensitivity and change in the spectrum of pathogens of community ronchopneumonia, as well as y the recommendations of international guidelines on macrolides as first-line preparations (especially in outpatient conditions). The association of cephalosporins with macrolides and fluoroquinolones is eneficial y covering the spectrum of atypical agents (Chlamydia pneumoniae, Legionella pneumophilla and Mycoplasma pneumoniae), microorganisms with an increasing share in the spectrum of infectious agents of community ronchopneumonia in adults.